Benign Prostatic Hyperplasia (BPH) Drugs Market Report

Japan Benign Prostatic Hyperplasia (BPH) Drugs Market Professional Research Report 2014-2026, Segmented by Players, Types, End-Users in Major Region

  • POSTDATE：Dec 19, 2019
  • PAGES：210
  • REPORT CODE：GMM403836
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • This report offers an overview of the market trends, drivers, and barriers with respect to the Japan Benign Prostatic Hyperplasia (BPH) Drugs market. It also provides a detailed overview of the market of different regions across Hokkaido, Tohoku, Kanto, Chubu, Kinki, Chugoku, Shikoku, Kyushu. The report deep analyzes type and application in Japan Benign Prostatic Hyperplasia (BPH) Drugs market. Detailed analysis of key players, along with key growth strategies adopted by Benign Prostatic Hyperplasia (BPH) Drugs industry, the PEST and SWOT analysis are also included. In short, the report will provide a comprehensive view of the industry's development and features.

    By Player:

    • GlaxoSmithKline

    • Madrigal Pharmaceuticals

    • Eli Lilly

    • ANI Pharmaceuticals

    • Endo Pharmaceuticals

    • Bayer HealthCare

    • Sanofi

    • Foresee Pharmaceuticals

    • Advaxis

    • Valeant Pharmaceuticals

    • Spectrum Pharmaceuticals

    • Merck

    • Novartis

    • Bristol-Myers Squibb

    • Takeda Pharmaceuticals

    • ADC Therapeutics

    • Teva

    • BHR Pharma

    • Astellas Pharma

    By Type:

    • Alpha-blocker

    • Phosphodiesterase Type-5 Inhibitors

    • 5-alpha-Reductase Inhibitors

    By End-User:

    • Hospitals

    • Clinics

    • Others

    By Region:

    • Hokkaido

    • Tohoku

    • Kanto

    • Chubu

    • Kinki

    • Chugoku

    • Shikoku

    • Kyushu

  • 1 Report Overview

    • 1.1 Product Definition and Scope

    • 1.2 PEST (Political, Economic, Social and Technological) Analysis of Benign Prostatic Hyperplasia (BPH) Drugs Market

    • 1.3 Market Segment by Type

      • 1.3.1 Japan Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate of Alpha-blocker from 2014 to 2026

      • 1.3.2 Japan Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate of Phosphodiesterase Type-5 Inhibitors from 2014 to 2026

      • 1.3.3 Japan Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate of 5-alpha-Reductase Inhibitors from 2014 to 2026

    • 1.4 Market Segment by Application

      • 1.4.1 Japan Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate of Hospitals from 2014 to 2026

      • 1.4.2 Japan Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate of Clinics from 2014 to 2026

      • 1.4.3 Japan Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate of Others from 2014 to 2026

    • 1.5 Market Segment by Regions

      • 1.5.1 Hokkaido Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Size and Growth Rate from 2014 to 2026

      • 1.5.2 Tohoku Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Size and Growth Rate from 2014 to 2026

      • 1.5.3 Kanto Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Size and Growth Rate from 2014 to 2026

      • 1.5.4 Chubu Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Size and Growth Rate from 2014 to 2026

      • 1.5.5 Kinki Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Size and Growth Rate from 2014 to 2026

      • 1.5.6 Chugoku Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Size and Growth Rate from 2014 to 2026

      • 1.5.7 Shikoku Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Size and Growth Rate from 2014 to 2026

      • 1.5.8 Kyushu Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Size and Growth Rate from 2014 to 2026

    2 Market Trends and Competitive Landscape

    • 2.1 Market Trends and Dynamics

      • 2.1.1 Market Challenges and Restraints

      • 2.1.2 Market Opportunities and Potentials

      • 2.1.3 Mergers and Acquisitions

    • 2.2 Competitive Landscape Analysis

      • 2.2.1 Industrial Concentration Analysis

      • 2.2.2 Porter's Five Forces Analysis of the Industry

      • 2.2.3 SWOT Analysis for New Entrants

    3 Segmentation of Benign Prostatic Hyperplasia (BPH) Drugs Market by Types

    • 3.1 Products Development Trends of Different Types

    • 3.2 Commercial Products Types of Major Vendors

    • 3.3 Competitive Landscape Analysis of Different Types

    • 3.4 Market Size of Benign Prostatic Hyperplasia (BPH) Drugs by Major Types

      • 3.4.1 Market Size and Growth Rate of Alpha-blocker

      • 3.4.2 Market Size and Growth Rate of Phosphodiesterase Type-5 Inhibitors

      • 3.4.3 Market Size and Growth Rate of 5-alpha-Reductase Inhibitors

    4 Segmentation of Benign Prostatic Hyperplasia (BPH) Drugs Market by End-Users

    • 4.1 Downstream Client Analysis by End-Users

    • 4.2 Competitive Landscape Analysis of Different End-Users

    • 4.3 Market Potential Analysis of Different End-Users

    • 4.4 Market Size of Benign Prostatic Hyperplasia (BPH) Drugs by Major End-Users

      • 4.4.1 Market Size and Growth Rate of Benign Prostatic Hyperplasia (BPH) Drugs in Hospitals

      • 4.4.2 Market Size and Growth Rate of Benign Prostatic Hyperplasia (BPH) Drugs in Clinics

      • 4.4.3 Market Size and Growth Rate of Benign Prostatic Hyperplasia (BPH) Drugs in Others

    5 Market Analysis by Regions

    • 5.1 Japan Benign Prostatic Hyperplasia (BPH) Drugs Production Analysis by Regions

    • 5.2 Japan Benign Prostatic Hyperplasia (BPH) Drugs Consumption Analysis by Regions

    6 Hokkaido Benign Prostatic Hyperplasia (BPH) Drugs Landscape Analysis

    • 6.1 Hokkaido Benign Prostatic Hyperplasia (BPH) Drugs Landscape Analysis by Major Types

    • 6.2 Hokkaido Benign Prostatic Hyperplasia (BPH) Drugs Landscape Analysis by Major End-Users

    7 Tohoku Benign Prostatic Hyperplasia (BPH) Drugs Landscape Analysis

    • 7.1 Tohoku Benign Prostatic Hyperplasia (BPH) Drugs Landscape Analysis by Major Types

    • 7.2 Tohoku Benign Prostatic Hyperplasia (BPH) Drugs Landscape Analysis by Major End-Users

    8 Kanto Benign Prostatic Hyperplasia (BPH) Drugs Landscape Analysis

    • 8.1 Kanto Benign Prostatic Hyperplasia (BPH) Drugs Landscape Analysis by Major Types

    • 8.2 Kanto Benign Prostatic Hyperplasia (BPH) Drugs Landscape Analysis by Major End-Users

    9 Chubu Benign Prostatic Hyperplasia (BPH) Drugs Landscape Analysis

    • 9.1 Chubu Benign Prostatic Hyperplasia (BPH) Drugs Landscape Analysis by Major Types

    • 9.2 Chubu Benign Prostatic Hyperplasia (BPH) Drugs Landscape Analysis by Major End-Users

    10 Kinki Benign Prostatic Hyperplasia (BPH) Drugs Landscape Analysis

    • 10.1 Kinki Benign Prostatic Hyperplasia (BPH) Drugs Landscape Analysis by Major Types

    • 10.2 Kinki Benign Prostatic Hyperplasia (BPH) Drugs Landscape Analysis by Major End-Users

    11 Chugoku Benign Prostatic Hyperplasia (BPH) Drugs Landscape Analysis

    • 11.1 Chugoku Benign Prostatic Hyperplasia (BPH) Drugs Landscape Analysis by Major Types

    • 11.2 Chugoku Benign Prostatic Hyperplasia (BPH) Drugs Landscape Analysis by Major End-Users

    12 Shikoku Benign Prostatic Hyperplasia (BPH) Drugs Landscape Analysis

    • 12.1 Shikoku Benign Prostatic Hyperplasia (BPH) Drugs Landscape Analysis by Major Types

    • 12.2 Shikoku Benign Prostatic Hyperplasia (BPH) Drugs Landscape Analysis by Major End-Users

    13 Kyushu Benign Prostatic Hyperplasia (BPH) Drugs Landscape Analysis

    • 13.1 Kyushu Benign Prostatic Hyperplasia (BPH) Drugs Landscape Analysis by Major Types

    • 13.2 Kyushu Benign Prostatic Hyperplasia (BPH) Drugs Landscape Analysis by Major End-Users

    14 Major Players Profiles

    • 14.1 GlaxoSmithKline

      • 14.1.1 GlaxoSmithKline Company Profile and Recent Development

      • 14.1.2 Market Performance

      • 14.1.3 Product and Service Introduction

    • 14.2 Madrigal Pharmaceuticals

      • 14.2.1 Madrigal Pharmaceuticals Company Profile and Recent Development

      • 14.2.2 Market Performance

      • 14.2.3 Product and Service Introduction

    • 14.3 Eli Lilly

      • 14.3.1 Eli Lilly Company Profile and Recent Development

      • 14.3.2 Market Performance

      • 14.3.3 Product and Service Introduction

    • 14.4 ANI Pharmaceuticals

      • 14.4.1 ANI Pharmaceuticals Company Profile and Recent Development

      • 14.4.2 Market Performance

      • 14.4.3 Product and Service Introduction

    • 14.5 Endo Pharmaceuticals

      • 14.5.1 Endo Pharmaceuticals Company Profile and Recent Development

      • 14.5.2 Market Performance

      • 14.5.3 Product and Service Introduction

    • 14.6 Bayer HealthCare

      • 14.6.1 Bayer HealthCare Company Profile and Recent Development

      • 14.6.2 Market Performance

      • 14.6.3 Product and Service Introduction

    • 14.7 Sanofi

      • 14.7.1 Sanofi Company Profile and Recent Development

      • 14.7.2 Market Performance

      • 14.7.3 Product and Service Introduction

    • 14.8 Foresee Pharmaceuticals

      • 14.8.1 Foresee Pharmaceuticals Company Profile and Recent Development

      • 14.8.2 Market Performance

      • 14.8.3 Product and Service Introduction

    • 14.9 Advaxis

      • 14.9.1 Advaxis Company Profile and Recent Development

      • 14.9.2 Market Performance

      • 14.9.3 Product and Service Introduction

    • 14.10 Valeant Pharmaceuticals

      • 14.10.1 Valeant Pharmaceuticals Company Profile and Recent Development

      • 14.10.2 Market Performance

      • 14.10.3 Product and Service Introduction

    • 14.11 Spectrum Pharmaceuticals

      • 14.11.1 Spectrum Pharmaceuticals Company Profile and Recent Development

      • 14.11.2 Market Performance

      • 14.11.3 Product and Service Introduction

    • 14.12 Merck

      • 14.12.1 Merck Company Profile and Recent Development

      • 14.12.2 Market Performance

      • 14.12.3 Product and Service Introduction

    • 14.13 Novartis

      • 14.13.1 Novartis Company Profile and Recent Development

      • 14.13.2 Market Performance

      • 14.13.3 Product and Service Introduction

    • 14.14 Bristol-Myers Squibb

      • 14.14.1 Bristol-Myers Squibb Company Profile and Recent Development

      • 14.14.2 Market Performance

      • 14.14.3 Product and Service Introduction

    • 14.15 Takeda Pharmaceuticals

      • 14.15.1 Takeda Pharmaceuticals Company Profile and Recent Development

      • 14.15.2 Market Performance

      • 14.15.3 Product and Service Introduction

    • 14.16 ADC Therapeutics

      • 14.16.1 ADC Therapeutics Company Profile and Recent Development

      • 14.16.2 Market Performance

      • 14.16.3 Product and Service Introduction

    • 14.17 Teva

      • 14.17.1 Teva Company Profile and Recent Development

      • 14.17.2 Market Performance

      • 14.17.3 Product and Service Introduction

    • 14.18 BHR Pharma

      • 14.18.1 BHR Pharma Company Profile and Recent Development

      • 14.18.2 Market Performance

      • 14.18.3 Product and Service Introduction

    • 14.19 Astellas Pharma

      • 14.19.1 Astellas Pharma Company Profile and Recent Development

      • 14.19.2 Market Performance

      • 14.19.3 Product and Service Introduction

     

    The List of Tables and Figures (Totals 90 Figures and 167 Tables)

    • Figure Japan Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate of Alpha-blocker from 2014 to 2026

    • Figure Japan Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate of Phosphodiesterase Type-5 Inhibitors from 2014 to 2026

    • Figure Japan Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate of 5-alpha-Reductase Inhibitors from 2014 to 2026

    • Figure Market Share by Type in 2014

    • Figure Market Share by Type in 2018

    • Figure Market Share by Type in 2026

    • Figure Japan Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate of Hospitals from 2014 to 2026

    • Figure Japan Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate of Clinics from 2014 to 2026

    • Figure Japan Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate of Others from 2014 to 2026

    • Figure Market Share by End-User in 2014

    • Figure Market Share by End-User in 2018

    • Figure Market Share by End-User in 2026

    • Figure Hokkaido Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Size and Growth Rate from 2014 to 2026

    • Figure Tohoku Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Size and Growth Rate from 2014 to 2026

    • Figure Kanto Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Size and Growth Rate from 2014 to 2026

    • Figure Chubu Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Size and Growth Rate from 2014 to 2026

    • Figure Kinki Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Size and Growth Rate from 2014 to 2026

    • Figure Chugoku Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Size and Growth Rate from 2014 to 2026

    • Figure Shikoku Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Size and Growth Rate from 2014 to 2026

    • Figure Kyushu Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Size and Growth Rate from 2014 to 2026

    • Figure Development Trends and Industry Dynamics of Benign Prostatic Hyperplasia (BPH) Drugs Industry

    • Figure Market Challenges and Restraints

    • Figure Market Opportunities and Potentials

    • Table Mergers and Acquisition

    • Figure Market Share of TOP 3 Players in 2018

    • Figure Market Share of TOP 5 Players in 2018

    • Figure Market Share of TOP 6 Players from 2014 to 2019

    • Figure Porter's Five Forces Analysis

    • Figure New Entrant SWOT Analysis

    • Table Specifications of Different Types of Benign Prostatic Hyperplasia (BPH) Drugs

    • Figure Development Trends of Different Types

    • Table Commercial Products Types of Major Vendors

    • Figure Competitive Landscape Analysis of Different Types

    • Table Consumption of Benign Prostatic Hyperplasia (BPH) Drugs by Different Types from 2014 to 2026

    • Table Consumption Share of Benign Prostatic Hyperplasia (BPH) Drugs by Different Types from 2014 to 2026

    • Figure Market Size and Growth Rate of Alpha-blocker

    • Figure Market Size and Growth Rate of Phosphodiesterase Type-5 Inhibitors

    • Figure Market Size and Growth Rate of 5-alpha-Reductase Inhibitors

    • Table Downstream Client Analysis by End-Users

    • Figure Competitive Landscape Analysis of Different End-Users

    • Table Market Potential Analysis of Different End-Users

    • Table Consumption of Benign Prostatic Hyperplasia (BPH) Drugs by Different End-Users from 2014 to 2026

    • Table Consumption Share of Benign Prostatic Hyperplasia (BPH) Drugs by Different End-Users from 2014 to 2026

    • Figure Japan Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate of Hospitals from 2014 to 2026

    • Figure Japan Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate of Clinics from 2014 to 2026

    • Figure Japan Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate of Others from 2014 to 2026

    • Table Japan Benign Prostatic Hyperplasia (BPH) Drugs Production by Regions

    • Table Japan Benign Prostatic Hyperplasia (BPH) Drugs Production Share by Regions

    • Figure Japan Benign Prostatic Hyperplasia (BPH) Drugs Production Share by Regions in 2014

    • Figure Japan Benign Prostatic Hyperplasia (BPH) Drugs Production Share by Regions in 2018

    • Figure Japan Benign Prostatic Hyperplasia (BPH) Drugs Production Share by Regions in 2026

    • Table Japan Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Regions

    • Table Japan Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by Regions

    • Figure Japan Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by Regions in 2014

    • Figure Japan Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by Regions in 2018

    • Figure Japan Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by Regions in 2026

    • Table Hokkaido Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Types from 2014 to 2026

    • Table Hokkaido Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by Types from 2014 to 2026

    • Figure Hokkaido Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by Types in 2014

    • Figure Hokkaido Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by Types in 2018

    • Figure Hokkaido Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by Types in 2026

    • Table Hokkaido Benign Prostatic Hyperplasia (BPH) Drugs Consumption by End-Users from 2014 to 2026

    • Table Hokkaido Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by End-Users from 2014 to 2026

    • Figure Hokkaido Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by End-Users in 2014

    • Figure Hokkaido Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by End-Users in 2018

    • Figure Hokkaido Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by End-Users in 2026

    • Table Tohoku Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Types from 2014 to 2026

    • Table Tohoku Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by Types from 2014 to 2026

    • Figure Tohoku Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by Types in 2014

    • Figure Tohoku Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by Types in 2018

    • Figure Tohoku Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by Types in 2026

    • Table Tohoku Benign Prostatic Hyperplasia (BPH) Drugs Consumption by End-Users from 2014 to 2026

    • Table Tohoku Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by End-Users from 2014 to 2026

    • Figure Tohoku Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by End-Users in 2014

    • Figure Tohoku Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by End-Users in 2018

    • Figure Tohoku Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by End-Users in 2026

    • Table Kanto Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Types from 2014 to 2026

    • Table Kanto Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by Types from 2014 to 2026

    • Figure Kanto Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by Types in 2014

    • Figure Kanto Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by Types in 2018

    • Figure Kanto Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by Types in 2026

    • Table Kanto Benign Prostatic Hyperplasia (BPH) Drugs Consumption by End-Users from 2014 to 2026

    • Table Kanto Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by End-Users from 2014 to 2026

    • Figure Kanto Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by End-Users in 2014

    • Figure Kanto Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by End-Users in 2018

    • Figure Kanto Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by End-Users in 2026

    • Table Chubu Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Types from 2014 to 2026

    • Table Chubu Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by Types from 2014 to 2026

    • Figure Chubu Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by Types in 2014

    • Figure Chubu Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by Types in 2018

    • Figure Chubu Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by Types in 2026

    • Table Chubu Benign Prostatic Hyperplasia (BPH) Drugs Consumption by End-Users from 2014 to 2026

    • Table Chubu Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by End-Users from 2014 to 2026

    • Figure Chubu Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by End-Users in 2014

    • Figure Chubu Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by End-Users in 2018

    • Figure Chubu Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by End-Users in 2026

    • Table Kinki Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Types from 2014 to 2026

    • Table Kinki Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by Types from 2014 to 2026

    • Figure Kinki Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by Types in 2014

    • Figure Kinki Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by Types in 2018

    • Figure Kinki Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by Types in 2026

    • Table Kinki Benign Prostatic Hyperplasia (BPH) Drugs Consumption by End-Users from 2014 to 2026

    • Table Kinki Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by End-Users from 2014 to 2026

    • Figure Kinki Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by End-Users in 2014

    • Figure Kinki Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by End-Users in 2018

    • Figure Kinki Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by End-Users in 2026

    • Table Chugoku Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Types from 2014 to 2026

    • Table Chugoku Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by Types from 2014 to 2026

    • Figure Chugoku Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by Types in 2014

    • Figure Chugoku Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by Types in 2018

    • Figure Chugoku Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by Types in 2026

    • Table Chugoku Benign Prostatic Hyperplasia (BPH) Drugs Consumption by End-Users from 2014 to 2026

    • Table Chugoku Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by End-Users from 2014 to 2026

    • Figure Chugoku Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by End-Users in 2014

    • Figure Chugoku Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by End-Users in 2018

    • Figure Chugoku Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by End-Users in 2026

    • Table Shikoku Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Types from 2014 to 2026

    • Table Shikoku Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by Types from 2014 to 2026

    • Figure Shikoku Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by Types in 2014

    • Figure Shikoku Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by Types in 2018

    • Figure Shikoku Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by Types in 2026

    • Table Shikoku Benign Prostatic Hyperplasia (BPH) Drugs Consumption by End-Users from 2014 to 2026

    • Table Shikoku Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by End-Users from 2014 to 2026

    • Figure Shikoku Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by End-Users in 2014

    • Figure Shikoku Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by End-Users in 2018

    • Figure Shikoku Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by End-Users in 2026

    • Table Kyushu Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Types from 2014 to 2026

    • Table Kyushu Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by Types from 2014 to 2026

    • Figure Kyushu Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by Types in 2014

    • Figure Kyushu Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by Types in 2018

    • Figure Kyushu Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by Types in 2026

    • Table Kyushu Benign Prostatic Hyperplasia (BPH) Drugs Consumption by End-Users from 2014 to 2026

    • Table Kyushu Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by End-Users from 2014 to 2026

    • Figure Kyushu Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by End-Users in 2014

    • Figure Kyushu Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by End-Users in 2018

    • Figure Kyushu Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by End-Users in 2026

    • Table Company Profile and Development Status of GlaxoSmithKline

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of GlaxoSmithKline

    • Figure Sales and Growth Rate Analysis of GlaxoSmithKline

    • Figure Revenue and Market Share Analysis of GlaxoSmithKline

    • Table Product and Service Introduction of GlaxoSmithKline

    • Table Company Profile and Development Status of Madrigal Pharmaceuticals

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Madrigal Pharmaceuticals

    • Figure Sales and Growth Rate Analysis of Madrigal Pharmaceuticals

    • Figure Revenue and Market Share Analysis of Madrigal Pharmaceuticals

    • Table Product and Service Introduction of Madrigal Pharmaceuticals

    • Table Company Profile and Development Status of Eli Lilly

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Eli Lilly

    • Figure Sales and Growth Rate Analysis of Eli Lilly

    • Figure Revenue and Market Share Analysis of Eli Lilly

    • Table Product and Service Introduction of Eli Lilly

    • Table Company Profile and Development Status of ANI Pharmaceuticals

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of ANI Pharmaceuticals

    • Figure Sales and Growth Rate Analysis of ANI Pharmaceuticals

    • Figure Revenue and Market Share Analysis of ANI Pharmaceuticals

    • Table Product and Service Introduction of ANI Pharmaceuticals

    • Table Company Profile and Development Status of Endo Pharmaceuticals

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Endo Pharmaceuticals

    • Figure Sales and Growth Rate Analysis of Endo Pharmaceuticals

    • Figure Revenue and Market Share Analysis of Endo Pharmaceuticals

    • Table Product and Service Introduction of Endo Pharmaceuticals

    • Table Company Profile and Development Status of Bayer HealthCare

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Bayer HealthCare

    • Figure Sales and Growth Rate Analysis of Bayer HealthCare

    • Figure Revenue and Market Share Analysis of Bayer HealthCare

    • Table Product and Service Introduction of Bayer HealthCare

    • Table Company Profile and Development Status of Sanofi

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Sanofi

    • Figure Sales and Growth Rate Analysis of Sanofi

    • Figure Revenue and Market Share Analysis of Sanofi

    • Table Product and Service Introduction of Sanofi

    • Table Company Profile and Development Status of Foresee Pharmaceuticals

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Foresee Pharmaceuticals

    • Figure Sales and Growth Rate Analysis of Foresee Pharmaceuticals

    • Figure Revenue and Market Share Analysis of Foresee Pharmaceuticals

    • Table Product and Service Introduction of Foresee Pharmaceuticals

    • Table Company Profile and Development Status of Advaxis

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Advaxis

    • Figure Sales and Growth Rate Analysis of Advaxis

    • Figure Revenue and Market Share Analysis of Advaxis

    • Table Product and Service Introduction of Advaxis

    • Table Company Profile and Development Status of Valeant Pharmaceuticals

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Valeant Pharmaceuticals

    • Figure Sales and Growth Rate Analysis of Valeant Pharmaceuticals

    • Figure Revenue and Market Share Analysis of Valeant Pharmaceuticals

    • Table Product and Service Introduction of Valeant Pharmaceuticals

    • Table Company Profile and Development Status of Spectrum Pharmaceuticals

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Spectrum Pharmaceuticals

    • Figure Sales and Growth Rate Analysis of Spectrum Pharmaceuticals

    • Figure Revenue and Market Share Analysis of Spectrum Pharmaceuticals

    • Table Product and Service Introduction of Spectrum Pharmaceuticals

    • Table Company Profile and Development Status of Merck

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Merck

    • Figure Sales and Growth Rate Analysis of Merck

    • Figure Revenue and Market Share Analysis of Merck

    • Table Product and Service Introduction of Merck

    • Table Company Profile and Development Status of Novartis

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Novartis

    • Figure Sales and Growth Rate Analysis of Novartis

    • Figure Revenue and Market Share Analysis of Novartis

    • Table Product and Service Introduction of Novartis

    • Table Company Profile and Development Status of Bristol-Myers Squibb

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Bristol-Myers Squibb

    • Figure Sales and Growth Rate Analysis of Bristol-Myers Squibb

    • Figure Revenue and Market Share Analysis of Bristol-Myers Squibb

    • Table Product and Service Introduction of Bristol-Myers Squibb

    • Table Company Profile and Development Status of Takeda Pharmaceuticals

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Takeda Pharmaceuticals

    • Figure Sales and Growth Rate Analysis of Takeda Pharmaceuticals

    • Figure Revenue and Market Share Analysis of Takeda Pharmaceuticals

    • Table Product and Service Introduction of Takeda Pharmaceuticals

    • Table Company Profile and Development Status of ADC Therapeutics

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of ADC Therapeutics

    • Figure Sales and Growth Rate Analysis of ADC Therapeutics

    • Figure Revenue and Market Share Analysis of ADC Therapeutics

    • Table Product and Service Introduction of ADC Therapeutics

    • Table Company Profile and Development Status of Teva

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Teva

    • Figure Sales and Growth Rate Analysis of Teva

    • Figure Revenue and Market Share Analysis of Teva

    • Table Product and Service Introduction of Teva

    • Table Company Profile and Development Status of BHR Pharma

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of BHR Pharma

    • Figure Sales and Growth Rate Analysis of BHR Pharma

    • Figure Revenue and Market Share Analysis of BHR Pharma

    • Table Product and Service Introduction of BHR Pharma

    • Table Company Profile and Development Status of Astellas Pharma

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Astellas Pharma

    • Figure Sales and Growth Rate Analysis of Astellas Pharma

    • Figure Revenue and Market Share Analysis of Astellas Pharma

    • Table Product and Service Introduction of Astellas Pharma

Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US